A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock

Juffermans, Nicole P.; Vervloet, Marc G.; Daemen-Gubbels, Catharina R.G.; Binnekade, Jan M.; Jong, Martin de; Groeneveld, A. B. Johan

doi:10.1016/j.niox.2010.01.006

Cited by 80 publications

(67 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Methylene blue had a dose-dependent effect on cardiac index, mean pulmonary artery and pulmonary artery occlusion pressure as well as oxygen delivery and lactate concentrations. The data suggested that in human septic shock, methylene blue increases mean arterial blood pressure through an increase in cardiac index and systemic vascular resistance [85].…”

Section: The No-cgmp Pathway In Anaphylaxis and The Role Of Methylenementioning

confidence: 99%

Methylene Blue for Distributive Shock: A Potential New Use of an Old Antidote

2013

View full text Add to dashboard Cite

Methylene blue is used primarily in the treatment of patients with methemoglobinemia. Most recently, methylene blue has been used as a treatment for refractory distributive shock from a variety of causes such as sepsis and anaphylaxis. Many studies suggest that the nitric oxidecyclic guanosine monophosphate (NO-cGMP) pathway plays a significant role in the pathophysiology of distributive shock. There are some experimental and clinical experiences with the use of methylene blue as a selective inhibitor of the NO-cGMP pathway. Methylene blue may play a role in the treatment of distributive shock when standard treatment fails.

show abstract

Section: The No-cgmp Pathway In Anaphylaxis and The Role Of Methylenementioning

confidence: 99%

Methylene Blue for Distributive Shock: A Potential New Use of an Old Antidote

2013

View full text Add to dashboard Cite

show abstract

“…In this study, MB was chosen as a NO scavenger as it has been shown to be a more effective NO scavenger compared to well-known NO scavenger, c-PTIO (Vandana et al, 2012). Methylene blue inhibits soluble guanylate cyclase and thereby the action of NO and cGMP (Juffermans et al, 2010). Nonetheless, MB also inhibits NO production by inhibiting inducible-NO synthase (Juffermans et al, 2010).…”

Section: Uranium Exposure Induces No Generationmentioning

confidence: 99%

“…Methylene blue inhibits soluble guanylate cyclase and thereby the action of NO and cGMP (Juffermans et al, 2010). Nonetheless, MB also inhibits NO production by inhibiting inducible-NO synthase (Juffermans et al, 2010).…”

Section: Uranium Exposure Induces No Generationmentioning

confidence: 99%

Uranium exposure induces nitric oxide and hydrogen peroxide generation in Arabidopsis thaliana

Tewari

Horemans

Nauts

et al. 2015

Environmental and Experimental Botany

View full text Add to dashboard Cite

“…Although it was later replaced by other drugs, there is renewed interest for the treatment of malaria with MB [16]. Some of the other useful applications of MB include: treatment for methaemoglobinaemia recommended by the WHO and the European Commission as antidote [17]; attenuating the pathogenic effects of sepsis; sentinel lymph node biopsy (SLNB) to differentiate the different tissues [18]; chromoperturbation and chromoendoscopy to localise Barrett's metaplasia [19,20]; inhibition of the actions of nitric oxide that lead to increased blood pressure and myocardial function [21,22]; treatment of anaphylaxis [23][24][25] by giving intravenously 1.5-2 mg/kg body weight [26].In all the above clinical applications the final amount of MB in the patient is considerably higher than when using MB plasma. Nevertheless, the potential side-effect of treated plasma remains to be fully elucidated by active haemovigilance at national and European levels by main users.…”

mentioning

confidence: 99%

Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction

Seghatchian¹,

Struff

Reichenberg

2011

Transfus Med Hemother

View full text Add to dashboard Cite

Methylene blue (MB) treated plasma has been in clinical use for 18 years. The current THERAFLEX MB-Plasma has a number of improved features compared with the original Springe methodology. This overview embodies: the biochemical characteristics of MB, the mechanism of the technology, toxicology, pathogen reduction capacity, current position in clinical setting and status within Europe. The THERAFLEX MB (TMB) procedure is a robust, well standardised system lending itself to transfusion setting and meets the current guidelines. The pathogen kill power of the TMB system, like the other available technologies, is not limitless, probably in order of 6 log for most enveloped viruses and considerably less for non-enveloped ones. It does not induce either new antigen or grossly reducing the function and life span of active principle in fresh frozen plasma (FFP). The removal of the residual MB at the end of the process has the beneficial effect of reducing potential toxic impacts. Clinical haemovigilance data, so far, indicate that cell-free MB plasma is effective in all therapeutic setting requiring FFP, besides inconsistent thrombotic thrombocytopenia purpura data, without serious side-effects or toxicity. The current system is in continuous improvement e.g. regarding virus reduction range, illumination device, software used, and process integration in the blood bank setting.

show abstract

A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock

Cited by 80 publications

References 28 publications

Methylene Blue for Distributive Shock: A Potential New Use of an Old Antidote

Methylene Blue for Distributive Shock: A Potential New Use of an Old Antidote

Uranium exposure induces nitric oxide and hydrogen peroxide generation in Arabidopsis thaliana

Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction

Contact Info

Product

Resources

About